Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our mission is to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Presenter report:Jaarsma, Tiny (Netherlands) The Coordinating study evaluating Outcomes of Advising and Counselling in Heart Failure (COACH) was a multicenter randomized controlled trial, in which 1023 patients were enrolled after hospitalization for HF. Patients were assigned to one of three groups: a control group (follow-up by cardiologist), and two intervention groups with additional basic, or intensive support by a HF nurse. Patients were studied for 18 months. Primary endpoints were time to death or rehospitalization for HF, and the number of days lost to death or hospitalization. Subgroup analysis were performed to determine possible heterogeneity in the effect of nurse-led heart failure care with regard to prespecified baseline variables.During the study 411 patients (40%) were readmitted for HF or died from any cause: 42% in the control group, and 41% and 38% in the basic and intensive support groups, respectively (p=0.53). The number of days lost to death or hospitalization was 39,960 in the control group, and it was 15% lower in the intervention groups combined (p=NS). There was a trend towards lower mortality in the intervention groups combined (HR 0.85; 95%, p=0.18). Subgroup analyses revealed that no significant treatment x subgroup interaction was found except for an interaction between depression and all cause mortality. Patients without depressive symptoms seem to benefit more from the basic or intensive support by a heart failure nurse compared to patients with depressive symptoms. Further studies to determine the most optimal model for heart failure disease management are needed.
Clinical Trial Update II
© 2017 European Society of Cardiology. All rights reserved